Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (564)	1/22/1998 12:08:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 1686

V1, Jim, thanks for the discussion on off-label use and the role of insurance or HMOs on this. I think getting a good grasp on this issue is important for evaluating the ultimate impact on drug developers of the recent FDA reforms, and of course, for estimating Avonex sales growth over the short and medium term. As I understand them, these reforms, among other things, make it easier for drug companies to promote off-label use of approved drugs. Ironically, this comes at a time in which, at least by my perception, third-party payors are increasingly reluctant to offer coverage for anything but the most "established" and "proven" treatments. I recently tried (I do mean "tried," this is boring stuff) to read some of the literature on this issue, and came across an article by a man from Kaiser-Permanente in the July 16 issue of JAMA. A Medline author search shows this guy has been busy writing about this and related issues over the last few years. The link to the JAMA article is: ama-assn.org Follow-up correspondence to the article came out in a November issue: ama-assn.org PB